BCG lmmunotherapy of Malignant Melanoma
- 1 October 1974
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 180 (4), 635-643
- https://doi.org/10.1097/00000658-197410000-00029
Abstract
Over the past 7 years, 151 patients with malignant melanoma have been treated with BCG immunotherapy alone or as an adjunct to surgical therapy. Direct injection of metastatic melanoma lesions limited to skin resulted in 90% regression of injected lesions and 17% regression of uninjected lesions in immunocompetent patients. Approximately 25% of these patients remained free of disease for 1 to 6 years. Direct injections of BCG into nodules of patients with subcutaneous or visceral metastases resulted in a lower incidence of local control and no long term survivors. Attempts to improve the results of immunotherapy in these patients by palliative surgical resection of large metastatic lesions to lower tumor burden followed by BCG immunotherapy significantly improved the results although many patients still developed recurrent disease. Early results of a clinical trial combining BCG immunotherapy with regional lymphadenectomy in patients with melanoma metastatic to lymph nodes have been encouraging and promising. Further controlled clinical trials are necessary to elucidate the role of BCG in immunotherapy. However, since BCG is but one of a number of potential immunologic adjuvants, even more effective immunotherapy will be possible as further knowledge of the interactions of cellular and humoral immunity is acquired.Keywords
This publication has 12 references indexed in Scilit:
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973
- Non-specific and specific immunotherapy in patients with melanoma.1972
- Demonstration of cell‐mediated immunity to human neoplasms of various histological typesInternational Journal of Cancer, 1971
- Immunological factors which influence response to immunotherapy in malignant melanoma.1970
- Impaired immunologic reactivity and recurrence following cancer surgeryCancer, 1970
- Tumour-specific Antibodies in Human Malignant Melanoma and their Relationship to the Extent of the DiseaseBMJ, 1969
- Detection by immunofluorescenge of antibodies specific for human malignant melanoma cellsCancer, 1969
- Suspension Culture of a Pigment-Producing Cell Line Derived From a Human Malignant Melanoma2JNCI Journal of the National Cancer Institute, 1968
- Demonstration of antibodies against human malignant melanoma by immunofluorescence.1968
- Maximum utilization of the life table method in analyzing survivalJournal of Chronic Diseases, 1958